X-LINKED CONGENITAL NEPHROGENIC DIABETES INSIPIDUS

Clinical trials for X-LINKED CONGENITAL NEPHROGENIC DIABETES INSIPIDUS explained in plain language.

Never miss a new study

Get alerted when new X-LINKED CONGENITAL NEPHROGENIC DIABETES INSIPIDUS trials appear

Sign up with your email to follow new studies for X-LINKED CONGENITAL NEPHROGENIC DIABETES INSIPIDUS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New pill aims to quench rare kidney Disorder's thirst for water

Disease control Not yet recruiting

This early-stage trial tests a daily capsule called NDI-5001 in 24 adult men with a rare inherited kidney disease that makes them produce huge amounts of urine and feel constantly thirsty. The main goal is to check the drug's safety and how it affects urine volume and concentrati…

Matched conditions: X-LINKED CONGENITAL NEPHROGENIC DIABETES INSIPIDUS

Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control

Last updated May 17, 2026 11:31 UTC

X-LINKED CONGENITAL NEPHROGENIC DIABETES INSIPIDUS

Get alerted when new X-LINKED CONGENITAL NEPHROGENIC DIABETES INSIPIDUS trials appear

New pill aims to quench rare kidney Disorder's thirst for water